{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:42:53Z","timestamp":1781113373397,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00415-024-12454-6","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:15:55Z","timestamp":1717589755000},"page":"5197-5202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6875-9613","authenticated-orcid":false,"given":"Charlotte","family":"H\u00e9raud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Bresch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandre","family":"Landes-Ch\u00e2teau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Bourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lebrun-Frenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"4","key":"12454_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"V Di Stefano","year":"2020","unstructured":"Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C (2020) Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 91(4):392\u2013395","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"12454_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"issue":"7","key":"12454_CR3","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","volume":"55","author":"F Zaja","year":"2000","unstructured":"Zaja F, Russo D, Fuga G, Perella G, Baccarani M (2000) Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 55(7):1062\u20131063","journal-title":"Neurology"},{"issue":"10","key":"12454_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 89(10):1069\u20131077","journal-title":"Neurology"},{"issue":"7","key":"12454_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","volume":"3","author":"D Anderson","year":"2016","unstructured":"Anderson D, Phan C, Johnston WS, Siddiqi ZA (2016) Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol 3(7):552\u2013555","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"12454_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK II, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 56(2):185\u2013196","journal-title":"Muscle Nerve"},{"issue":"11","key":"12454_CR7","first-page":"e19416","volume":"13","author":"S Bastakoti","year":"2021","unstructured":"Bastakoti S, Kunwar S, Poudel S, Quinonez J, Bista S, Singh N et al (2021) Rituximab in the management of refractory myasthenia gravis and variability of its efficacy in anti-MuSK positive and anti-AChR positive myasthenia gravis. Cureus\u00a013(11):e19416","journal-title":"Cureus"},{"issue":"1","key":"12454_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology. 55(1):16\u201323","journal-title":"Neurology."},{"issue":"6","key":"12454_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","volume":"5","author":"E Cort\u00e9s-Vicente","year":"2018","unstructured":"Cort\u00e9s-Vicente E, Rojas-Garcia R, D\u00edaz-Manera J, Querol L, Casasnovas C, Guerrero-Sola A et al (2018) The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol 5(6):710\u2013716","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"12454_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.nmd.2016.12.004","volume":"27","author":"V Afanasiev","year":"2017","unstructured":"Afanasiev V, Demeret S, Bolgert F, Eymard B, Lafor\u00eat P, Benveniste O (2017) Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients. Neuromuscul Disord 27(3):251\u2013258","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"12454_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","volume":"32","author":"M Caballero-\u00c1vila","year":"2022","unstructured":"Caballero-\u00c1vila M, \u00c1lvarez-Velasco R, Moga E, Rojas-Garcia R, Turon-Sans J, Querol L et al (2022) Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. Neuromuscul Disord 32(8):664\u2013671","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"12454_CR12","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","volume":"6","author":"KM Kanth","year":"2016","unstructured":"Kanth KM, Solorzano GE, Goldman MD (2016) PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract 6(2):e17\u2013e19","journal-title":"Neurol Clin Pract"},{"issue":"3","key":"12454_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","volume":"266","author":"R Topakian","year":"2019","unstructured":"Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K et al (2019) High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol 266(3):699\u2013706","journal-title":"J Neurol"},{"issue":"5","key":"12454_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Alboini PE, Evoli A (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262(5):1115\u20131119","journal-title":"J Neurol"},{"key":"12454_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA et al (2022) Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 79:1105\u20131112","journal-title":"JAMA Neurol."},{"key":"12454_CR16","unstructured":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study\u2014PubMed [Internet]. [cited 2023 Nov 28]. https:\/\/pubmed.ncbi.nlm.nih.gov\/22941747\/"},{"issue":"3","key":"12454_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, Klooster R, Rojas-Garc\u00eda R, Su\u00e1rez-Calvet X et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78(3):189\u2013193","journal-title":"Neurology"},{"issue":"1","key":"12454_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2016.4190","volume":"74","author":"KR Robeson","year":"2017","unstructured":"Robeson KR, Kumar A, Keung B, DiCapua DB, Grodinsky E, Patwa HS et al (2017) Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol 74(1):60\u201366","journal-title":"JAMA Neurol"},{"issue":"3","key":"12454_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","volume":"58","author":"G Beecher","year":"2018","unstructured":"Beecher G, Anderson D, Siddiqi ZA (2018) Rituximab in refractory myasthenia gravis: extended prospective study results. Muscle Nerve 58(3):452\u2013455","journal-title":"Muscle Nerve"},{"issue":"2","key":"12454_CR20","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s13311-021-01006-9","volume":"18","author":"C Ruetsch-Chelli","year":"2021","unstructured":"Ruetsch-Chelli C, Bresch S, Seitz-Polski B, Rosenthal A, Desnuelle C, Cohen M et al (2021) Memory B cells predict relapse in rituximab-treated myasthenia gravis. Neurotherapeutics 18(2):938\u2013948","journal-title":"Neurotherapeutics"},{"issue":"5","key":"12454_CR21","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R et al (2022) Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 1(5):EVIDoa2100066. https:\/\/doi.org\/10.1056\/EVIDoa2100066","journal-title":"NEJM Evid."},{"issue":"2","key":"12454_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM197401102900204","volume":"290","author":"ME Seybold","year":"1974","unstructured":"Seybold ME, Drachman DB (1974) Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med. 290(2):81\u20134","journal-title":"N Engl J Med."},{"issue":"5","key":"12454_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/jnnp-2017-316625","volume":"89","author":"T Imai","year":"2018","unstructured":"Imai T, Utsugisawa K, Murai H, Tsuda E, Nagane Y, Suzuki Y et al (2018) Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan. J Neurol Neurosurg Psychiatry 89(5):513\u2013517","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12454-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12454-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:13:42Z","timestamp":1723475622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12454-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["12454"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12454-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study complied with good clinical practice guidelines and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}